Chinese Clinical Oncology

• 论著 • Previous Articles     Next Articles

Clinical observation of neoadjuvant chemotherapy with docetaxel plus lobaplatin regimen in triple negative breast cancer〖

YAO Yufeng, GONG Jianping, TANG Jinhai, QIN Jianwei.   

  1. Department of General Surgery, Tumor Hospital of Jiangsu Province
  • Received:2013-03-17 Revised:2013-05-17 Online:2013-08-31 Published:2013-08-31
  • Contact: GONG Jianping

Abstract: Objective To evaluate the efficacy and adverse reaction of neoadjuvant chemotherapy with docetaxel plus lobaplatin regimen in triple negative breast cancer (TNBC). Methods Thirty TNBC patients accepted neoadjuvant chemotherapy with docetaxel and lobaplatin(docetaxel 75mg/m2 iv, d1; lobaplatin 30mg/m2 iv, d1; 21 days was a cycle). The objective response and side effects were evaluated by WHO standard or histopathological reaction after surgery. Results Eight patients finished chemotherapy for 2 cycles, 17 patients for 4 cycles and 5 patients for 6 cycles. All patients were evaluable, 9 cases got CR, 15 cases got PR, 4 cases had SD, 2 cases were PD. The clinical benefit rate was 80.0%. Six cases achieved pCR according to the histopathological detection after surgery. The main adverse reaction was myelosuppression,with grade 12 leukopenia in 17 cases, grade 34 leukopenia in 5 cases, grade 1-2 thrombocytopenia in 7 cases, grade 3-4 thrombocytopenia in 2 cases and grade 12 anemia in 6 cases. Nonhemotologic toxicities were modest and recoverable. Conclusion Neoadjuvant chemotherapy with docetaxel plus lobaplatin regimen in TNBC is effective and well tolerated,which gives us a new choice.

No related articles found!
Viewed
Full text
318
HTML PDF
Just accepted Online first Issue Just accepted Online first Issue
0 0 0 0 0 318

  From Others local
  Times 29 289
  Rate 9% 91%

Abstract
117
Just accepted Online first Issue
0 0 117
  From Others
  Times 117
  Rate 100%

Cited

Web of Science  Crossref   ScienceDirect  Search for Citations in Google Scholar >>
 
This page requires you have already subscribed to WoS.
  Shared   
  Discussed   
No Suggested Reading articles found!